A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/1999
12/23/1999	CA2334528A1 Regulation of tyrosine hydroxylase
12/23/1999	CA2334369A1 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
12/23/1999	CA2334254A1 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
12/23/1999	CA2333666A1 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
12/23/1999	CA2333554A1 Cyclic hydroxamic acids as metalloproteinase inhibitors
12/23/1999	CA2333453A1 Methods for increasing levels of acetylcholine
12/23/1999	CA2333384A1 Methods for reducing levels of homocysteine and c-reactive protein
12/23/1999	CA2332997A1 A process for the treatment of organophosphate poisoning
12/23/1999	CA2332325A1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
12/23/1999	CA2332173A1 A vaccine-induced hepatitis b viral strain and uses thereof
12/23/1999	CA2331834A1 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
12/23/1999	CA2331382A1 Interaction of p27(kip1) with fkbp-12
12/23/1999	CA2331332A1 Anti-angiogenic proteins and methods of use thereof
12/23/1999	CA2331154A1 Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
12/23/1999	CA2331151A1 Monoclonal antibodies directed against the g3bp protein, and uses
12/23/1999	CA2330840A1 Diagnostic method based on quantification of extramitochondrial dna
12/23/1999	CA2330527A1 Erythropoietin analog-human serum albumin fusion
12/23/1999	CA2330210A1 Proteasomal activity
12/23/1999	CA2301665A1 Methods and compositions for treatment of aids-associated kaposi's sarcoma
12/23/1999	CA2300892A1 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
12/22/1999	EP0965587A1 Tetrahydropyridinyl- and piperidinyl Inhibitors of serotonin reuptake
12/22/1999	EP0965351A2 Pharmaceutical composition for treating side-effects of a diet with reduced amount of carbohydrates
12/22/1999	EP0965345A2 Use of acemannan
12/22/1999	EP0965342A1 Preparation for percutaneous administration
12/22/1999	EP0965341A2 Combination of dofetilide and a calcium channel blocker
12/22/1999	EP0965278A1 Dietetic food composition and dietetic method using such composition
12/22/1999	EP0964917A1 Age-1 polypeptides and related molecules and methods
12/22/1999	EP0964864A2 Pyrido 2,3-d] pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
12/22/1999	EP0964863A1 Oxazolidines as 5-ht2a-antagonists
12/22/1999	EP0964860A1 Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
12/22/1999	EP0964856A1 Bicyclic amino acids
12/22/1999	EP0964852A1 Indolecarboxylic compounds and their use as pharmaceutical compounds
12/22/1999	EP0964851A1 C-terminal ketone hydroxamic acid inhibitors of matrix metalloproteinases and tnfa secretion
12/22/1999	EP0964696A1 Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
12/22/1999	EP0964689A1 Recombinant vaccine for diseases caused by encapsulated organisms
12/22/1999	EP0964680A1 Use of nitric oxide inhibitors for treating side effects of particulate drugs
12/22/1999	EP0964679A1 Method for the treatment of neurological or neuropsychiatric disorders
12/22/1999	EP0939628A4 Thiol sulfone metalloprotease inhibitors
12/22/1999	EP0910385A4 Sensitization of cells to radiation and chemotherapy
12/22/1999	EP0876160B1 Ligand directed enzyme prodrug therapy
12/22/1999	EP0758312B1 Substituted fused and bridged bicyclic compounds as therapeutic agents
12/22/1999	EP0733033B1 Pharmaceutically active substituted aromatic compounds
12/22/1999	EP0726954B1 Cytokine antagonists
12/22/1999	EP0726893B1 Novel 4-piperidinyl substituted lactames as neurokinin 2 receptor antagonists for the treatment of asthma
12/22/1999	EP0711167A4 Methods of enhancing opiate analgesic potency or detoxifying an opiate addict
12/22/1999	EP0684953A4 Adenosine kinase inhibitors comprising lyxofuranosyl derivatives.
12/22/1999	EP0659083B1 Prevention and treatment of peripheral neuropathy
12/22/1999	EP0635018B1 4-(1H-2-METHYLIMIDAZO[4,5-c]PYRIDINYLMETHYL)PHENYLSULPHONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF
12/22/1999	CN1239510A Compsns. and methods for treating disease states with myeloid progenitor inhibitory factor-1(MPIF-1), monocyte colony inhibitory factor (M-CIF) and macrophage inhibitory factor-4(MIP-4)
12/22/1999	CN1239435A Methods and compsns. for stimulating neurite growth using compounds with affinity for FKBP12 in combination with neurotrophic factors
12/22/1999	CN1238988A Medicine for treating apoplexy and its preparing process
12/21/1999	US6005117 Imino compounds, process for their preparation and their use as victronectin antagonists
12/21/1999	US6005115 Forms A and B of N-[[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl ]thio]ethyl]ami no]methylene]-4-bromo-benzenesulfonamide
12/21/1999	US6005098 Nucleoside derivative which can be administered with 5-fluorouracil to enhance antitumor activity
12/21/1999	US6005010 Cardiovascular disorders, antiarrhythmia agents and antiischemic agents
12/21/1999	US6005000 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
12/21/1999	US6004991 Compounds for cosmetics with enantiomorphs
12/21/1999	US6004987 Use of ligands which are specific for RXR receptors
12/21/1999	US6004974 Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines
12/21/1999	US6004953 Administering synergistic mixture of ascorbic acid and cobalt or iron phthalo- or naphthalocyanine complex; side effect reduction; anticarcinogenic agents; catalysis
12/21/1999	US6004937 Treating muscular and nervous system disorders
12/21/1999	US6004931 Method for inhibiting growth hormone action
12/21/1999	US6004794 Human serine protease
12/21/1999	US6004579 Aging inhibition; wound healing agent; preserving organs; treating dermatological conditions such as wrinkling, sagging, baldness, psoriasis
12/21/1999	US6004552 Administration of a monoclonal antibody capable of binding to a human cd40 antigen located on the surface of a human b cell, wherein the binding of the antibody to the cd40 antigen prevents the growth or differentiation of the b cell
12/21/1999	US6004550 Intracellular expression of carboxypeptidase G2 in a nitrogen mustard prodrug system
12/21/1999	US6004299 Injection vessel and solution-enclosed injection vessel in use thereof
12/21/1999	CA2135850C Esculetin derivatives, and method for manufacture thereof, use thereof, and pharmaceutical composition
12/21/1999	CA2060624C Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
12/21/1999	CA1340855C Neurite-promoting factor and process for the manufacture thereof
12/16/1999	WO1999064622A1 Inhibition of coagulation in blood and blood products
12/16/1999	WO1999064606A1 Tankyrase, a trfi binding protein
12/16/1999	WO1999064596A2 Proteins regulating gene expression
12/16/1999	WO1999064593A2 Cell cycle regulation proteins
12/16/1999	WO1999064586A2 Phagocytic assay method
12/16/1999	WO1999064585A2 Novel angiotensin receptor, production and use thereof
12/16/1999	WO1999064574A1 Method to prepare c-terminal modified peptides
12/16/1999	WO1999064572A2 Poly(adp-ribose) polymerase gene
12/16/1999	WO1999064463A1 Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples
12/16/1999	WO1999064462A1 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
12/16/1999	WO1999064453A1 Purification process for production of mannan-binding lectin and an mbl medicinal product
12/16/1999	WO1999064442A1 Peptide inhibitors of hepatitis c virus ns3 protease
12/16/1999	WO1999064426A1 Heterobicyclic and tricyclic nitric oxide synthase inhibitors
12/16/1999	WO1999064423A1 Furopyridine derivatives and their therapeutical use
12/16/1999	WO1999064422A1 Pyrido[2,3-b]indolizine derivatives and aza analogues thereof; crf1 specific ligands
12/16/1999	WO1999064421A1 Acetylcholine enhancers
12/16/1999	WO1999064420A1 β-CARBOLINE COMPOUNDS
12/16/1999	WO1999064419A1 Pyrrole derivatives, preparation method and pharmaceutical compositions containing same
12/16/1999	WO1999064415A1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
12/16/1999	WO1999064414A1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
12/16/1999	WO1999064412A1 Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
12/16/1999	WO1999064411A1 Tetrahydroquinoline derivatives as glycine antagonists
12/16/1999	WO1999064406A1 A process for the preparation of macrocyclic metalloprotease inhibitors
12/16/1999	WO1999064403A1 1,5-benzodiazepine derivatives
12/16/1999	WO1999064401A2 Imidazolyl derivatives and their use as somatostatin receptor ligands
12/16/1999	WO1999064399A1 Protease inhibitors
12/16/1999	WO1999064390A1 Phenylalanine derivatives as integrin inhibitors
12/16/1999	WO1999064388A1 Hyperforin derivatives, the use thereof and formulations containing them
12/16/1999	WO1999064072A1 Conjugate consisting of a lectin and a blood coagulation factor
12/16/1999	WO1999064061A1 GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE

1 ... 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 ... 1564